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INTRODUCTION:  Retroperitoneal  sarcomas  have  rarely  been  reported  to  secrete  insulin-growth  factor  II
(IGF-II)  and  produce  an enigmatic  hypoglycemia.  IGF-II-secreting  sarcomas  represent  an  extremely  rare
subset  of soft  tissue  tumors,  and  reports  are  limited  to a handful  of  cases.
PRESENTATION  OF CASE:  The  authors  present  the  case  of  hypoglycemia  due  to  an  IGF-II-secreting  retroperi-
toneal sarcoma  that  was  successfully  treated  by complete  surgical  resection.  This  report  describes  theeywords:
ypoglycemia
etroperitoneal mass
nsulin-like growth factor
diagnosis  and  management  of  this  rare syndrome  with  1-year  follow-up  and  a review  of  the literature.
DISCUSSION:  Steroid  and  growth  hormone  therapies  also  have  efﬁcacy  to treat  this  hypoglycemia  in  some
patients.  However,  outcomes  appear  better  if combined  with  surgical  resection.
CONCLUSIONS:  The  ﬁndings  of this  case  report  and review  of  the  literature  support  a primary  role  for
complete  tumor  resection  to  address  tumor-induced  hypoglycemia.
© 2014  Published  by Elsevier  Ltd.  on  behalf of Surgical  Associates  Ltd.  This  is an  open  access  article
under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Hypoglycemia is a rare but potentially life-threatening presen-
ation of soft tissue tumors the etiology of hypoglycemia may  be
ifﬁcult to diagnose. Retroperitoneal sarcomas have rarely been
eported to secrete insulin-growth factor II (IGF-II) which can lead
o low blood glucose levels. IGF-II-secreting sarcomas represent an
xtremely rare subset of soft tissue tumors, and there is no consen-
us on the ideal management of the hypoglycemia associated with
his tumor-type. Here we present a case report of hypoglycemia
ith a large retroperitoneal mass and review of the literature.
. Presentation of the case
A 38-year-old diabetic man  presented with increasing episodes
f hypoglycemia over the previous 8 months. As a consequent, his
nsulin had been discontinued 5 months prior, despite a long history
f insulin-dependent diabetes. He also complained of increas-
ng abdominal girth over the previous several months and 15
ound weight loss. A varicocele was discovered by ultrasound
fter complaints of worsening right testicular pain. Biochemical
ork-up revealed blood glucose level was very low at 32 mg/DL.
Abbreviations: F, female; GH, recombinant human growth hormone; M,  male;
O,  months; NR, not reported; RP, Retroperitoneum; YR, years.
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ttp://dx.doi.org/10.1016/j.ijscr.2014.11.013
210-2612/© 2014 Published by Elsevier Ltd. on behalf of Surgical Associate
http://creativecommons.org/licenses/by-nc-nd/3.0/).Total and free insulin levels were <1.2 and <1.5 IU/mL (normal:
0–22 IU/mL), respectively. Elevated Insulin-Like Growth Factor
(IGF)-II level was  944 ng/mL (normal: 288–736 ng/mL). IGF-1 lev-
els were reduced and C-peptide levels were undetectable (normal:
1.1–4.4 nL/mL). Computer tomography (CT) of abdomen demon-
strated a large right retroperitoneal tumor involving the right
kidney and displacing the IVC and liver (Fig. 1A).
The patient was  admitted preoperatively for intravenous dex-
trose while unable to eat prior to surgery. He underwent an en
block tumor resection via a chevron incision secondary to the size
of the mass. After the celiotomy, a large mass arising from the
retroperitoneum was  encountered occupying the majority of the
right hemi-abdomen (Fig. 1B). During tumor extirpation, a plane
could not be developed between the mass and right kidney. There-
fore, a right nephrectomy was included in the en block resection. The
tumor weighed 3.25 kg and measured 19.5 cm × 17.2 cm × 13.5 cm
(Fig. 1B, inset). Pathological examination using stains, immunohis-
tochemistry, electron microscopy and molecular and cytogenetic
studies showed a primitive, undifferentiated mesenchymal tumor
(sarcoma).
After surgery, the patient was taken to the intensive care unit
for blood sugar monitoring. The expected half-lives of free IGF-II
and carrier protein-bound IGF-II in a healthy male are 10–12 min
and 12–15 h, respectively.1 However, immediately postoperatively,
the patient’s glucose levels elevated to the 200s mg/dL. He was
started on an insulin drip with intravenous dextrose and then was
transitioned to subcutaneous insulin with resumption of a diet. He
was discharged home on postoperative day 6 with a serum glucose
range 90–237 mg/dL. Within one month, the patient’s IGF-II level
returned to normal (317 ng/mL) with a serum glucose of 170 mg/dL.
s Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Evaluation and resection of IGF-II-secreting retroperitoneal tumor. (A) Coronal computed tomography shows a retroperitoneal tumor involving the right kidney and
displacing the inferior vena cava and liver. (B) A very large mass occupied the right hemiabdomen. Inset shows the gross pathology specimen, resected en block. Bar indicates
3  cm.
Table 1
Hypoglycemia associated with IGF-II secreting tumors – literature review.
Reference Age, sex Symptoms Tumor pathology,
location
Treatment Hypoglycemia outcome Oncologic outcome
Rose et al.4 54, F Fatigue Mesenchymal solid
ﬁbrous tumor,
Abdominal cavity
1. Intratumoral alcohol
injections
Persistent hypoglycemia
and death in 24 h
Not applicable
Early satiety 2. Surgical debulking
Weight loss
Teale and Wark3
(8 cases: A–H)
34–81 Drowsiness A. Carcinoma, lung A. Steroids only A. Resolved, 5 MO A. NR
Coma  B. Fibroma, thoracic B. Steroids only B. Resolved, 8 MO  B. Recur, 8 MO
Otherwise NR C. Spindle-cell, NR C. Debulking/Steroids C. Resolved, 9 MO C. NR
D.  Sarcoma, RP D.
Resection/chemo/steroids
D. Resolved, 6 MO D. NR
E.  Sarcoma, NR E. Steroids only E. Not resolved E. NR
F.  Carcinoma, prostate F. Steroids/resection F. Resolved F. NR
G.  Sarcoma, NR G. Resection G. Resolved G. NR
H.  Fibroma, pleura H. Resection H. Resolved H. NR
Bourcigaux et al.8 67, F Acromegaly Pleural ﬁbroma,
hemithorax
1. Chronic steroids Resolution of
hypoglycemia with
combined steroids and
GH
NR
2. GH
3. Steroids and GH
Chan et al.7 70, M Loss of
consciousness
Fibrosarcoma, liver 1. Embolization Resolved, 9 MO  Recurrence, 1 YR
2.  Complete resection
De  Groot et al.6 83, M Confusion Solid ﬁbrous tumor,
kidney
Complete resection and
nephrectomy en block
Resolution of
hypoglycemia and
normalization of glucose
and IGF-II
NR
Lethargy
48,  F Coma Metastatic
hemangiopericytoma,
liver
1. Chronic steroids Free of hypoglycemic
events through 1-YR
follow up
Stable disease, 1 YR
2. Chemotherapy
Dutta et al.5 77, M Loss of
consciousness
Sarcoma,
retroperitoneum
1. Debulking Free of hypoglycemic
events through 6-YR
follow up
Residual disease, 1 YR
2.  Chemotherapy Asymptomatic, 6 YR
3.  Radiotherapy Then lost to follow up
4.  Chronic steroids
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Table  1 (Continued)
Reference Age, sex Symptoms Tumor pathology,
location
Treatment Hypoglycemia outcome Oncologic outcome
24, F Hunger Hemangiopericytoma,
left upper abdomen
1. Chemotherapy Free of hypoglycemic
events through 3-YR
follow up
No recurrence, 3 YR
Sweating 2. Complete resection
with splenectomy,
nephrectomy, partial
pancreatectomy en block
Tremors
32, F Neuroglycopenia Adrenocortical
carcinoma, suprarenal
Complete resection with
adrenalectomy en block
Free of hypoglycemic
events through 1-YR
follow up
No recurrence, 6 YR
80,  M Cough Pleural mesothelioma,
internal chest wall
Chronic steroids
(declined surgery and
chemotherapy)
Immediate hypoglycemic
episodes subsided but
lost to follow-up
Lost to follow up
Breathlessness
Seizures
48,  M Abdominal
pain
Leiomyosarcoma, RP and
abdomen
Complete resection Free of hypoglycemic
events through 6 MO
No recurrence, 6 MO
Hawasli et al.
(2014)
38, M Neuroglycopenia Mesenchymal tumor,
retroperitoneum
Complete resection with
nephrectomy en block
Free of hypoglycemic
events through 4 MO
No recurrence, 4 MO
F  = not 
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 = female; GH = recombinant human growth hormone; M = male; MO  = months; NR
ne-year post-operatively, he has returned to normal activities. He
as had no further episodes of hypoglycemia, and his serum glucose
evel was elevated at 237 mg/dL, for which he is being evaluated for
n insulin pump.
. Discussion and literature review
Patients with non-islet cell tumors secreting IGF-II can have
ypoglycemia because of increased glucose uptake into peripheral
nsulin target tissues and suppressed hepatic glucose production.2
herefore, tumor-induced hypoglycemia should be considered in a
atient with low blood glucose, low C-peptide, low fasting insulin
evels and weight loss.3–8
Management of hypoglycemia in a patient with an IGF-II-
ecreting tumor remains under some deliberation. As shown
n Table 1, Rose et al. reported on a 54 year old woman
ith an IGF-II secreting abdominal mesenchymal tumor lead-
ng to malignant hypoglycemia.4 Despite intratumoral alcohol
njections and surgical debulking, this patient died 24 h after
urgery due to persistent hypoglycemia. Teale et al. reported on
 cases of hypoglycemia due to IGF-II-secreting tumors.3 They
oncluded that chronic steroid therapy may  successfully treat
ypoglycemia in some patients and complete surgical resection
s recommended when possible. De Groot et al. reported on two
dult patients with IGF-II-secreting tumors: one with a “solid
brous tumor” of the kidney and another with a metastatic
emangiopericytoma.6 The ﬁrst patient’s hypoglycemia immedi-
tely resolved after resection of the kidney mass. The second patient
arbored several unresectable masses. With chronic corticosteroid
herapy and chemotherapy, this patient remained free of hypo-
lycemic events for more than a year.6 Bourcigaux et al. reported
esolution of hypoglycemia with combined chronic steroids and
ecombinant human growth hormone.8 Chan et al. reported resolu-
ion of hypoglycemia after steroids and complete resection.7 Dutta
t al. reported 5 IGF-II-secreting tumors including a retroperitoneal
arcoma, hemangiopericytoma, adrenocortical carcinoma, pleu-
al mesothelioma and a retroperitoneal leiomyosarcoma.5 Four
atients underwent complete resections and all remained free from
ypoglycemic events at follow up (6 months-6 years). One patient
howed stable tumor disease while the other four showed no
ecurrence.reported; RP = retroperitoneum; YR = years.
4. Conclusion
This case and review of the literature show that the most effec-
tive treatment for hypoglycemia due to an IGF-II-secreting sarcoma
is complete surgical resection.4–6 If the tumor is not resectable
and diet with glucose supplementation do not address the hypo-
glycemia, glucocorticoids and growth hormone may help in mildly
symptomatic patients.4–6 Other treatments such as chemotherapy,
radiotherapy, tumor embolization and alcohol injections into the
tumor have been used but seem to have little effect on hypo-
glycemia induced by IGF-II secreting soft tissue masses.4–6 In
summary, we report a case of a 38-year-old who presents with
hypoglycemia due to an IGF-II-secreting retroperitoneal undif-
ferentiated mesenchymal tumor that was successfully treated by
surgical resection.
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